Dark Classics in Chemical Neuroscience: Mescaline

The paper is a narrative review rather than a systematic review or meta-analysis; the extracted text does not provide explicit methods for literature search, inclusion criteria, or a date range for sources. Instead, the authors integrate archaeological, ethnobotanical, chemical, biosynthetic, pharmacological and behavioural literature spanning the late 19th century to late 20th century and selectively discuss more recent molecular work where available. Coverage in the review includes archaeological and historical records of cactus use, botanical taxonomy and variability in alkaloid content, the history of mescaline isolation and chemical syntheses, studies of biosynthesis in cacti (notably tyrosine-derived pathways), in vitro and in vivo pharmacology in animals and humans, pharmacokinetics and metabolism, and structure–activity relationship work that produced more potent phenethylamine and amphetamine derivatives. Where the primary literature supplies quantitative data (for example, mescaline concentrations in plant tissues or pharmacokinetic parameters), the authors report those values; however, methodological details for the cited original studies are not systematically tabulated in the extracted text.

History, botany and occurrence: Archaeological records and pre-Columbian iconography establish millennia-long use of mescaline-containing cacti. Peyote (L. williamsii) and San Pedro/wachuma (T. pachanoi, T. peruvianus, T. bridgesii) are the principal botanical sources for human consumption because they contain relatively high mescaline levels. Measured mescaline concentrations vary substantially by species, plant part and provenance: crowns of individual peyote plants contained about 1.82–5.5% mescaline (dry weight) in one study, while green tissue of T. pachanoi specimens ranged from 0.54% to 4.7% in another analysis. Several species and varieties contain low or negligible mescaline, and within-plant distribution typically concentrates mescaline in green, chlorophyll-containing tissues (tops or crowns). Chemistry, synthesis and biosynthesis: The chemical structure of mescaline (3,4,5-trimethoxyphenethylamine) was established by synthesis in 1929 and multiple synthetic routes were developed subsequently. Historical synthetic methods include nitrostyrene reduction, LAH reductions, and alternative modern routes; labelled precursors were used to prepare radiolabelled mescaline for early pharmacokinetic work. Biosynthetic studies, principally using 14C-labelled precursors in the 1960s, support a tyrosine-derived pathway (the Lundström and Agurell scheme). More recently, candidate genes for tyrosine/DOPA decarboxylase, hydroxylases and O-methyltransferases have been identified in L. williamsii tissue, providing a molecular starting point for further biosynthetic investigation. Pharmacology and behavioural pharmacology: Early human observations (late 19th and early 20th century) described characteristic psychedelic effects—visual alterations, distortions of time and sensory intensification—together with variable affective responses; individual responses could differ markedly between occasions. Oral doses around 300 mg of the free base are reported as typical for a full psychedelic experience, and smaller clinical/historical doses (for example, Heffter’s 0.15 g of mescaline hydrochloride) produced perceptual effects with delayed onset. Pharmacodynamics: Binding studies summarised by the authors indicate mescaline interacts primarily with serotonergic receptors—5-HT2A and 5-HT1A—and also shows appreciable affinity for α2A adrenergic receptors, with little evidence for significant D2 dopaminergic binding. Behavioural assays in rodents show mescaline elicits the head-twitch response (a serotonergic 5-HT2A-mediated proxy for psychedelic activity), disrupts prepulse inhibition (indicating impaired sensorimotor gating), and produces biphasic effects on locomotion (low-dose hyperlocomotion, high-dose hypolocomotion), consistent with engagement of different 5-HT receptor subtypes. Some early pharmacology implicated mixed serotonergic and catecholaminergic effects, and electrophysiological work pointed to modulation of cortical pyramidal neurons, particularly in layer V. Pharmacokinetics and metabolism: Human pharmacokinetic data summarised in the review indicate mescaline is largely excreted unchanged in urine and is eliminated almost completely within 48 hours, with a plasma half-life of roughly 6 hours. Urinary radioactivity peaked around the second hour after oral administration of labelled mescaline in early studies. Oxidative deamination to the corresponding phenylacetaldehyde, and subsequent formation of the acid and alcohol, is a major metabolic pathway; N-acetylated and O-demethylated metabolites are also reported, and N-acetyl derivatives were comparatively abundant in human cerebrospinal fluid in one early study. The authors note that investigation into human metabolism and pharmacokinetics waned after the 1970s. Structure–activity relationships (SAR) and analogues: The mescaline scaffold served as the template for extensive SAR work that produced more potent phenethylamine and amphetamine analogues. Examples include α-methylmescaline (TMA), considered somewhat more potent than mescaline in early human tests, and amphetamine-type derivatives such as DOM that are reported to be 80–100 times more potent than mescaline. The 2,5-dimethoxy substitution pattern with a small hydrophobic 4-substituent emerged as a near‑optimal motif for potency in many analogues. More recent classes, including NBOMe derivatives, further increased potency and became focal points for research and recreational use. Despite some analogues having higher 5-HT2A affinity, differences in behavioural substitution (for example, incomplete substitution in LSD-trained animals) indicate functional and subjective differences among compounds. Gaps and limitations reported in the results: The authors stress that pharmacological research on mescaline has been fragmentary and largely historical, with little modern work on its human neurobiology. They highlight variability in plant mescaline content, incomplete characterisation of plant companion alkaloids and their effects on mescaline pharmacokinetics, and a lack of contemporary human mechanistic studies.

Cassels and Sáez-Briones position mescaline as a historically important and pharmacologically informative psychedelic that has been relatively neglected by modern research. They interpret the long ethnobotanical record and the compound’s role as the principal active of peyote and San Pedro to support the view that mescaline remains an important benchmark for understanding classic serotonergic hallucinogens. At the same time, the authors argue that mescaline’s low potency relative to many synthetic analogues partly explains its limited recreational popularity and the historical focus on creating more potent derivatives. The review emphasises that mescaline’s pharmacology appears more complex than a simple 5-HT2A agonist model might imply. Reported binding to 5-HT1A and α2A receptors, along with distinctive behavioural profiles in animals and early human observations, suggest differences in mechanism and subjective effects compared with LSD and other psychedelics. The authors note electrophysiological and behavioural evidence linking mescaline to modulation of cortical pyramidal neurons and striato‑limbic systems, and they discuss how functional selectivity at 5-HT2A/2C receptors could contribute to compound-specific effects. Key limitations and uncertainties are acknowledged: the extracted text reports a dearth of recent human pharmacology, incomplete and largely historic pharmacokinetic and metabolism data (studies largely ceased after the 1970s), high variability in mescaline content across cactus species and within individual plants, and insufficient attention to the potential influence of co-occurring cactus alkaloids on mescaline’s absorption and metabolism. The authors therefore call for renewed multidisciplinary work, including more detailed biosynthetic studies (building on preliminary gene candidates), modern pharmacokinetic and receptor‑mechanism investigations in humans, and systematic analyses of plant chemistry. They suggest such work could clarify mescaline’s distinctive properties among classic psychedelics and inform both basic neuroscience and potential therapeutic exploration, while recognising that definitive clinical applications remain unestablished and would require contemporary clinical trials and safety assessment.